clascoteronecb-03-01androgenetic alopecia
Clascoterone (CB-03-01): Patient Data and Real-World Effectiveness
Phase 2 dose-ranging trials confirm that topical clascoterone (CB-03-01) delivers meaningful terminal hair gains without the systemic sexual side effects of oral 5-alpha reductase inhibitors. Here is an authentic examination of the clinical trial data, dosing protocols, and real-world efficacy.
Sep 6, 2026·2 months ago